rs2070803 — MUC1

Near-gene regulatory variant that reduces MUC1 mucin expression on the gastric epithelium, impairing mucosal barrier defense and increasing susceptibility to diffuse-type gastric cancer

See your personal result for MUC1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MUC1 Near-Gene Variant — The Stomach's Mucus Shield and Gastric Cancer Risk

The gastric epithelium is under constant assault — acid, pepsin, ingested pathogens, and the chronic coloniser Helicobacter pylori11 Helicobacter pylori
A gram-negative bacterium that infects the stomach lining of roughly half the global population; the primary causal agent of peptic ulcers and a major risk factor for gastric cancer. The first line of defence is a thick mucus layer anchored by mucin glycoproteins, the most important of which is MUC122 MUC1
Mucin 1, a high-molecular-weight, heavily O-glycosylated transmembrane protein expressed on the apical surface of gastric epithelial cells; it provides both steric hindrance against pathogens and acts as a releasable decoy. rs2070803 is a regulatory variant near the MUC1 gene on chromosome 1q22 that influences how much of this protective protein the stomach produces. Carrying one or two copies of the A allele is associated with lower MUC1 surface expression — and, in some of the largest genetic studies ever conducted on gastric cancer, a meaningfully elevated risk of developing diffuse-type gastric cancer33 diffuse-type gastric cancer
One of two major histological subtypes of gastric cancer (alongside intestinal-type); diffuse-type spreads through the stomach wall without forming a distinct mass and carries a worse prognosis.

The Mechanism

rs2070803 maps approximately 585 base pairs upstream of the MUC1 transcription start site on the reverse strand, placing it in the gene's regulatory region. It is in strong linkage disequilibrium44 linkage disequilibrium
Non-random co-inheritance of nearby variants; alleles at linked sites are more often inherited together than expected by chance with the functionally characterised variant rs4072037, which directly alters MUC1 promoter activity and controls the ratio of major MUC1 splice variants produced in the gastric epithelium.

Carriers of the A allele at rs2070803 produce less MUC1 protein at the gastric mucosal surface. This reduction compromises the epithelium in two ways. First, MUC1's extracellular domain normally acts as a steric barrier against bacterial adhesion — its dense glycan coat is physically too large to allow most bacteria to reach the underlying cell membrane. Second, MUC1 functions as a releasable decoy: shed extracellular domain fragments bind pathogen adhesins and carry them away from the epithelium. With less surface MUC1, both mechanisms are weakened.

H. pylori further compounds genetically reduced expression. The virulence factor CagA55 CagA
Cytotoxin-associated gene A protein, injected directly into gastric epithelial cells by H. pylori; once inside, it is tyrosine-phosphorylated and disrupts multiple host signalling pathways is injected into host cells, where it undergoes phosphorylation and promotes binding of MUC1's cytoplasmic tail to β-catenin. The resulting MUC1–β-catenin complex translocates to the nucleus, activating proliferative gene programmes including cyclin-D1. Carriers who already have lower baseline MUC1 expression due to the A allele are therefore more vulnerable to this CagA-driven oncogenic cascade.

The Evidence

The primary evidence comes from a genome-wide association study66 genome-wide association study
Saeki N et al. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology, 2011 conducted across three panels of Japanese and Korean individuals (discovery: 606 cases/1,264 controls; validation 1: 304 cases/1,465 controls; validation 2: 452 cases/372 controls). rs2070803 reached genome-wide significance with p = 4.33 × 10⁻¹³ and a meta-analytic odds ratio of 1.71 for diffuse-type gastric cancer. Notably, the association was specific to diffuse-type and not intestinal-type gastric cancer.

A complementary case-control study77 case-control study
Xu L et al. Risk of gastric cancer is associated with the MUC1 568 A/G polymorphism. Int J Oncol, 2009 directly measured MUC1 protein in gastric tissue: AA genotype carriers showed significantly lower MUC1 immunostaining (r = −0.179, p = 0.004) and a 1.81-fold increased gastric cancer risk, providing the functional link between genotype and reduced mucosal protection.

A systematic review and meta-analysis88 systematic review and meta-analysis
Giraldi L et al. MUC1, MUC5AC, and MUC6 polymorphisms, Helicobacter pylori infection, and gastric cancer. Eur J Cancer Prev, 2018 of 21 studies confirmed the protective effect of the G allele (OR 0.66, 95% CI 0.57–0.78 for dominant model AG/GG vs. AA), with consistent findings across Asian (OR 0.73) and White European (OR 0.48) populations.

The risk is further amplified when rs2070803 co-occurs with the PSCA risk variant rs2294008. Carriers of risk alleles at both loci face a dramatically higher combined gastric cancer risk, as these two genes act in partially overlapping mucosal defence pathways.

Practical Implications

This variant is a genuine gastric cancer susceptibility signal — not a certainty, but a meaningful elevation in lifetime risk that is actionable. The most direct intervention is targeted H. pylori screening, since the genetic risk is substantially mediated through the bacteria's ability to exploit weakened mucosal defences. Current evidence suggests that eradicating H. pylori reduces gastric cancer incidence by roughly 35–45% in infected individuals, and for A allele carriers the absolute benefit may be larger because the residual mucosal vulnerability is genetically amplified.

Dietary and supplement strategies that support mucosal integrity — specifically those with evidence in the gastric context — complement surveillance without replacing it. Antral gastroscopy99 gastroscopy
Direct visual inspection of the stomach lining using an endoscope surveillance intervals recommended by gastroenterologists should be followed by anyone who also has chronic gastritis, intestinal metaplasia, or a family history of gastric cancer.

Interactions

rs2070803 is in strong linkage disequilibrium with rs4072037, the functionally characterised MUC1 promoter variant. These two SNPs tag the same haplotype in most studies and their associations are not independent — the risk captured by rs2070803 is largely the same risk captured by rs4072037.

The PSCA variant rs2294008 represents a separate pathway (prostate stem cell antigen, expressed in gastric epithelium) that interacts epistatically with MUC1 variants. Carriers of both MUC1 and PSCA risk alleles face substantially higher combined risk than either alone, as documented in the original Saeki et al. GWAS.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal MUC1 Expression Normal

Protective genotype — full MUC1 mucosal expression, lower gastric cancer risk

The G allele at rs2070803 tags a haplotype associated with higher MUC1 promoter activity and greater surface expression of the MUC1 mucin in gastric epithelial cells. Functional studies show that GG individuals have significantly more MUC1 protein detectable by immunohistochemistry in non-neoplastic gastric tissue compared to AA individuals.

From a mechanistic standpoint, abundant surface MUC1 provides two-layer protection: the dense glycan forest of the MUC1 ectodomain sterically prevents most bacteria from reaching the cell membrane directly, and shed MUC1 ectodomains in the mucus layer act as decoys that bind and sequester bacterial adhesins. This is particularly relevant for Helicobacter pylori, which uses BabA and SabA adhesins to colonise the gastric epithelium.

The GWAS by Saeki et al. 2011 showed that GG individuals served as the reference group in a meta-analysis demonstrating OR 1.71 for diffuse-type gastric cancer in A allele carriers — meaning GG genotype carries the lowest observed risk in the study population.

AG Intermediate MUC1 Expression Intermediate

One risk allele — modestly reduced mucosal MUC1, intermediate gastric cancer risk

The additive inheritance pattern means that one copy of the A allele partially reduces MUC1 surface expression, but the single functional G-allele haplotype provides enough compensatory mucin production to maintain reasonable barrier function. The clinical significance of heterozygosity is therefore intermediate — real but not as prominent as homozygous A.

The Xu et al. 2009 study measured MUC1 protein levels directly in gastric tissue and found a dose-dependent relationship: AA individuals had the lowest expression, AG individuals were intermediate, and GG individuals had the highest MUC1 levels (correlation r = −0.179 with the A allele count). This tissue-level evidence is consistent with a haploinsufficiency-like effect rather than full recessivity.

From a public health standpoint, heterozygous individuals in high-gastric-cancer-risk populations (East Asia, Eastern Europe, Central and South America) may benefit from earlier or more proactive H. pylori screening, since the environmental risk and genetic risk compound each other.

AA Low MUC1 Expression High Risk

Two risk alleles — significantly reduced mucosal MUC1, elevated diffuse-type gastric cancer risk

AA homozygotes show the lowest MUC1 immunostaining in gastric tissue compared to AG and GG individuals. The correlation between A allele dose and reduced MUC1 protein (r = −0.179, p = 0.004 in the Xu et al. 2009 study) provides direct functional evidence that this is not a passive statistical association but a real reduction in mucosal barrier capacity.

The gastric mucosa of AA individuals is more permeable to H. pylori colonisation, and once the bacterium establishes itself, its CagA virulence factor further reduces MUC1 by hijacking the β-catenin–MUC1 cytoplasmic tail interaction and redirecting it toward proliferative gene activation. This creates a compounding vulnerability: less surface MUC1 to block colonisation, and then reduced ability to resist CagA-mediated oncogenic signalling once colonisation occurs.

The risk is specific to diffuse-type gastric cancer (also called signet ring cell carcinoma), which is the more aggressive of the two major gastric cancer subtypes. It tends to present at a younger age, spreads through the stomach wall without forming a visible mass (making endoscopic detection harder), and carries a worse 5-year survival than intestinal-type.

Active H. pylori eradication in infected individuals reduces overall gastric cancer incidence by approximately 35–45%. For AA genotype carriers with confirmed infection, prompt eradication and subsequent monitoring are the highest-yield interventions.